retatrutide clinical trial results 2024 2025 press release Lilly's triple agonist delivers up to 71.2 lbs of weight loss

Clinical trial results for retatrutide, Eli Lilly's next weight loss drug, showed far more weight loss than other blockbuster obesity drugs. More below ⬇️

23.88

★★★★☆4.8 (126)

First phase 3 data for retatrutide are here folks. This drug is a barn burner. This was only 68 weeks and was geared towards osteoarthritis of the knee. Massive pain improvements and

23.48

★★★★★4.9 (98)

First phase 3 data for retatrutide are here folks. This drug is a barn burner. This was only 68 weeks and was geared towards osteoarthritis of the knee. Massive pain improvements and

23.82

★★★★★5.0 (157)

Clinical trial results for retatrutide, Eli Lilly's next weight loss drug, showed far more weight loss than other blockbuster obesity drugs. More below ⬇️

23.59

★★★★★4.7 (84)

Retatrutide produces up to 30.3% weight loss in Phase 3 trial

26.27

★★★★★4.9 (203)

Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce knee arthritis pain in a late-stage clinical trial, the company announced

24.40

★★★★★5.0 (176)

The Retatrutide Dosage Chart

23.24

★★★★★4.8 (132)